Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst

Moderna, Inc. MRNA shares have rallied since the start of July, rendering the valuation unattractive and "ridiculous," according to a BofA Securities analyst. 

The Moderna Analyst: Geoff Meacham maintained an Underperform rating on Moderna with a $115 price target.

The Moderna Thesis: At a roughly $200-billion market value, Moderna has eclipsed pharma industry veterans Merck & Co., Inc. MRK, Bristol-Myers Squibb Company BMY and Amgen, Inc. AMGN, Meacham said in a Tuesday note. 

The latter three companies, the analyst said, are therapeutics businesses with proven long-term track records and deep/ diversified late-stage pipelines. 

Related Link: The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

To justify Moderna's $200-billion valuation, the company needs to sell 1.5 billion doses of COVID-19 vaccine each year from 2022 through 2038, and its entire pipeline must succeed with aggregate peak sales of $30 billion, Meacham said.

"These assumptions are, in our view, impossible to justify," the analyst said.

A $485 fair value for the share would require cumulative COVID-19 vaccine sales of $340 billion through 2038, contributing $280 per share, and a pipeline value of $170 per share, which represents a 100% success rate for four Phase 2 programs, 10 Phase 1 programs and 8 preclinical programs, he said. 

Feedback from infectious disease experts, Meacham said, provides support for a skeptical longer-term view of COVID-19 vaccines, even with the emergence of variants like delta.

MRNA Price Action: At last check, Moderna shares were down 5.69% to $456.88. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

How to Buy Moderna MRNA Stock 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechHealth CarePrice TargetReiterationTop StoriesAnalyst RatingsMoversTrading IdeasGeneralBofA SecuritiesCoronavirusCovid-19Geoff Meachamvaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!